Fungal infections after hematopoietic cell transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1346-1366

  Brown, Janice M Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Approach to patient with suspected invasive fungal disease following HCT; Aspergillosis: clinical syndromes; Emerging fungal infections; Fungal infections after hematopoietic cell transplantation; Immune response to Aspergillus spp; Investigational immunotherapy pulsed DCs and graft modification; Preparative regimen, graft manipulation, progenitor cells

Indexed keywords

EID: 84873714576     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch89     Document Type: Chapter

References (180)

1. Grow WB, Moreb JS, Roque D et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-19.
2. Zaoutis TE, Heydon K, Chu JH et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: 711-16.
3. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
4. Kleinberg M. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Med Mycol 2005; 43(Suppl 1): S289-94.
5. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
6. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17: 10-13.
7. Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-82.
8. Roychowdhury M, Pambuccian SE, Aslan DL et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med 2005; 129: 366-7.
9. van Burik JH, Leisenring W, Myerson D et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-54.
10. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl 1): S49-58.
11. Dvorak CC, Steinbach WJ, Brown JM et al. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005; 36: 621-9.
12. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case fatality rate. A systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
13. Nosari A, Oreste P, Cairoli R et al. Invasive Aspergillosis in hematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001; 68: 231-6.
14. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a singlecenter study of 166 transplanted patients. Transpl Infect Dis 2007; 9: 189-95.
15. Williamson EC, Millar MR, Steward CG et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560-8.
16. Baddley JW, Stroud TP, Salzman D et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24.
17. Heurlin N, Bergstrom SE, Winiarski J et al. Fungal pneumonia: the predominant lung infection causing death in children undergoing bone marrow transplantation. Acta Paediatr 1996; 85: 168-72.
18. Mencacci A, Cenci E, Bacci A et al. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J Infect Dis 2000; 181: 686-94.
19. Maraki S, Hajiioannou I, Anatoliotakis N et al. Ceftriaxone and dexamethasone affecting yeast gut flora in experimental mice. J Chemother 1999; 11: 363-6.
20. Mavromanolakis E, Maraki S, Cranidis A et al. The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. Scand J Infect Dis 2001; 33: 477-8.
21. Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999; 37: 531-7.
22. Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 1996; 22(Suppl 2): S73-88.
23. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia, pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
24. Pfaller MA. Nosocomial candidiasis. Emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(Suppl 2): S89-94.
25. Klepser ME. Antifungal resistance among Candida species. Pharmacotherapy 2001; 21: S124-32.
26. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526-30.
27. Marr KA, Seidel K, White TC et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
28. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001; 7(Suppl 2): 1-7.
29. Chryssanthou E, Cherif H, Petrini B et al. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scand J Infect Dis 2004; 36: 855.
30. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infect Dis Clin North Am 2000; 30: 662-78.
31. Edwards JE Jr. Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
32. Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 1989; 8: 99-104.
33. Rossetti F, Brawner DL, Bowden R et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995; 20: 801-11.
34. Semelka RC, Kelekis NL, Sallah S et al. Hepatosplenic fungal disease: diagnostic accuracy and spectrum of appearances on MR imaging. AJR Am J Roentgenol 1997; 169: 1311-16.
35. Franquet T, Müller NL, Lee KS, Oikonomou A, Flint JD. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings. Radiology 2005; 236: 332-7.
36. von Eiff M, Roos N, Schulten R et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341-7.
37. Salamon SA, Fuursted K, Egeblad H et al. Candida albicans tricuspid and pulmonic valve endocarditis: challenge of relapsing risk and role of combined medical treatment and surgery. Scand J Infect Dis 2007; 39: 641-4.
38. Jimenez-Exposito MJ, Torres G, Baraldes A et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004; 39: e70-3.
39. Steinbach WJ, Perfect JR, Cabell CH et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infec 2005; 51: 230-47.
40. Breit SM, Hariprasad SM, Mieler WF. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135-40.
41. Thiel MA, Zinkernagel AS, Burhenne J et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007; 51: 239-44.
42. Bunya VY, Hammersmith KM, Rapuano CJ et al. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol 2007; 143: 151-3.
43. Mattiuzzi G, Giles FJ. Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 2005; 131: 287-300.
44. Hamadeh R, Ardehali A, Locksley RM et al. Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest 1988; 94: 432-3.
45. Warris A, Gaustad P, Meis JF et al. Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect 2001; 47: 143-8.
46. Ng TT, Robson GD, Denning DW. Hydrocortisone- enhanced growth of Aspergillus spp. implications for pathogenesis. Microbiology 1994; 140: 2475-9.
47. Duong M, Ouellet N, Simard M et al. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis 1998; 178: 1472-82.
48. Heidenreich S, Kubis T, Schmidt M et al. Glucocorticoid-induced alterations of monocyte defense mechanisms against Candida albicans. Cell Immunol 1994; 157: 320-7.
49. Neth O, Jack DL, Dodds AW et al. Mannosebinding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68: 688-93.
50. Nierman WC, Pain A, Anderson MJ et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 2005; 438: 1151-6.
51. Chandrasekar PH. Empirical antifungal therapy for persistent fever in patients with neutropenia. Clin Infect Dis 2001; 32: 320-1.
52. Jantunen E, Piilonen A, Volin L et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000; 25: 867-71.
53. Escuissato DL, Gasparetto EL, Marchiori E et al. Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. AJR Am J Roentgenol 2005; 185: 608-15.
54. Schueller G, Matzek W, Kalhs P, Schaefer-Prokop C. Pulmonary infections in the late period after allogeneic bone marrow transplantation: chest radiography versus computed tomography. Eur J Radiol 2005; 53: 489-94.
55. Kojima R, Tateishi U, Kami M et al. Computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 506-11.
56. Bissinger AL, Einsele H, Hamprecht K et al. Infectious pulmonary complications after stem cell transplantation or chemotherapy: diagnostic yield of bronchoalveolar lavage. Diagn Microbiol Infect Dis 2005; 52: 275-80.
57. Jantunen E, Piilonen A, Volin L et al. Radiologically guided fine needle lung biopsies in the evaluation of focal pulmonary lesions in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2002; 29: 353-6.
58. van Assen S, Bootsma GP, Verweij PE et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1131-2.
59. Machida U, Kami M, Kanda Y et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1145-9.
60. Hagensee ME, Bauwens JE, Kjos B et al. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center 1984-92. Clin Inf Dis 1994; 19: 402-8.
61. Jantunen E, Violin I, Salonen O et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003; 31: 191-6.
62. Schwartz S, Ruhnke M, Ribaud P et al. Poor effi- cacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 2007; 50: 196-200.
63. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood 2005; 106: 2641-5.
64. Mattiuzzi G, Giles FJ. Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 2005; 131: 287-300.
65. Choi JH, Yoo JH, Chung IJ et al. Esophageal aspergillosis after bone marrow transplant. Bone Marrow Transplant 1997; 19: 293-4.
66. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7(Suppl 2): 8-24.
67. Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002; 17: 113-20.
68. Torres HA, Rivero GA, Lewis RE et al. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003; 46: 25-8.
69. Machetti M, Feasi M, Mordini N et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998; 21: 917-21.
70. Viscoli C, Machetti M, Cappellano P et al. Falsepositive galactomannan platelia Aspergillus test results for patients receiving piperacillintazobactam. Clin Infect Dis 2004; 38: 913-16.
71. Steinbach WJ, Addison RM, McLaughlin L et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007; 26: 558-64.
72. Busca A, Locatelli F, Barbui A et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006; 38: 1610-13.
73. Maertens JA, Klont R, Masson C et al. A number optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329-36.
74. Marr KA, Balajee SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-9.
75. Weisser M, Rausch C, Droll A et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005; 41: 1143-9.
76. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939-43.
77. Hebart H, Loffler J, Reitze H et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 2000; 111: 635-40.
78. Halliday C, Hoile R, Sorrell T et al. Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. Br J Haematol 2006; 132: 478-86.
79. White PL, Linton CJ, Perry MD et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-86.
80. Buchheidt D, Baust C, Skladny H et al. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 2002; 116: 803-11.
81. Musher B, Fredricks D, Leisenring W et al. Aspergillus galactomannan immunoassay and quantitative PCR diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517-22.
82. Clemons KV, Calich VL, Burger E et al. Pathogenesis. I. Interactions of host cells and fungi. Med Mycol 2000; 38(Suppl 1): 99-111.
83. Kullberg BJ, Netea MG, Vonk AG et al. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Microbiol 1999; 26: 299-307.
84. Newman SL, Holly A. Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells. Infect Immun 2001; 69: 6813-22.
85. Farah CS, Elahi S, Drysdale K et al. Primary role for CD4+ T lymphocytes in recovery from oropharyngeal candidiasis. Infect Immun 2002; 70: 724-31.
86. Jones-Carson J, Vazquez-Torres A, Warner T et al. Disparate requirement for T cells in resistance to mucosal and acute systemic candidiasis. Infect Immun 2000; 68: 2363-5.
87. Balish E, Warner T, Pierson CJ et al. Oroesophageal candidiasis is lethal for transgenic mice with combined natural killer and T-cell defects. Med Mycol 2001; 39: 261-8.
88. Brieland JK, Jackson C, Menzel F et al. Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect Immun 2001; 69: 1554-60.
89. Liu L, Kang K, Takahara M et al. Hyphae and yeasts of Candida albicans differentially regulate interleukin-12 production by human blood monocytes: inhibitory role of C. albicans germination. Infect Immun 2001; 69: 4695-7.
90. Mencacci A, Perruccio K, Bacci A et al. Defective antifungal T-helper 1 (Th1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with Th2 cytokine antagonists. Blood 2001; 97: 1483-90.
91. Tuite A, Mullick A, Gros P. Genetic analysis of innate immunity in resistance to Candida albicans. Genes Immun 2004; 5: 576-87.
92. Zarember KA, Sugui JA, Chang YC et al. Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrinmediated iron depletion. J Immunol 2007; 178: 6367-73.
93. Rivera A, Van Epps HL, Hohl TM et al. Distinct CD4+-T-cell responses to live and heatinactivated Aspergillus fumigatus conidia. Infect Immun 2005; 73: 7170-9.
94. de Repentigny L, Petitbois S, Boushira M et al. Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun 1993; 61: 3791-802.
95. Richard JL, Thurston JR, Cutlip RC et al. Vaccination studies of aspergillosis in turkeys: subcutaneous inoculation with several vaccine preparations followed by aerosol challenge exposure. Am J Vet Res 1982; 43: 488-92.
96. Serrano-Gomez D, Dominguez-Soto A, Ancochea J et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin medi ates binding and internalization of Aspergillus fumigatus conidia by dendritic cells and macrophages. J Immunol 2004; 173: 5635-43.
97. Bozza S, Gaziano R, Spreca A et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002; 168: 1362-71.
98. Cenci E, Mencacci A, Del Sero G et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999; 180: 1957-68.
99. Centeno-Lima S, Silveira H, Casimiro C et al. Kinetics of cytokine expression in mice with invasive aspergillosis: lethal infection and protection. FEMS Immunol Med Microbiol 2002; 32: 167-73.
100. Grazziutti ML, Rex JH, Cowart RE et al. Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis 1997; 176: 1579-83.
101. Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol 2005; 129: 583-96.
102. Beck O, Topp MS, Koehl U et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 2006; 107: 2562-9.
103. Perruccio K, Tosti A, Burchielli E et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397-406.
104. Shah AJ, Kapoor N, Crooks GM et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant 2007; 13: 584-93.
105. Mohty M, Jacot W, Faucher C et al. Infectious complications following allogeneic HLAidentical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168-77.
106. Morrison BE, Park SJ, Mooney JM, Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 2003; 112: 1862-7.
107. Kesh S, Mensah NY, Peterlongo P et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005; 1062: 95-103.
108. Brummer E, Kamberi M, Stevens DA. Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. Infect Dis 2003; 187: 705-9.
109. Brummer E, Choi JH, Stevens DA. Interaction between conidia, lung macrophages, immunosuppressants, proinflammatory cytokines and transcriptional regulation. Med Mycol 2005; 43(Suppl 1): S177-9.
110. Marty FM, Lee SJ, Faey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-76.
111. Frere P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol 2006; 76: 102-8.
112. Jantunen E, Salonen J, Juvonen E et al. Invasive fungal infections in autologous stem cell transplant recipients: a nationwide study of 1188 transplanted patients. Eur J Haematol 2004; 73: 174-8.
113. Hagen EA, Stern H, Porter D et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36: 9-15.
114. Busca A, Locatelli F, Barbui A et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2003; 5: 132-9.
115. Delgado J, Thomson K, Russell N et al. British Society of Blood and Marrow Transplantation. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006; 107: 1724-30.
116. Brunstein CG, Barker JN, Weisdorf DJ et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 2007; 110: 3064-70.
117. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol 2006; 135: 423-37.
118. Anaissie EJ, Stratton SL, Dignani MC et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002; 35: E86-8.
119. Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 659-727.
120. BitMansour A, Brown JM. Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. J Infect Dis 2002; 186: 134-7.
121. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebocontrolled trial. Blood 2000; 96: 2055-61.
122. MacMillan ML, Goodman JL, DeFor TE et al. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112: 369-79.
123. Kami M, Machida U, Okuzumi K et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002; 117: 40-6.
124. Ullmann AJ, Cornely OA. Prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19: 571-6.
125. O'Donnell MR, Schmidt GM, Tegtmeier BR et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827-34.
126. Conneally E, Cafferkey MT, Daly PA et al. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403-6.
127. Alexander BD, Dodds Ashley ES et al. Noncomparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8: 13-20.
128. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007; 78: 275-82.
129. Mehta P, Vinks A, Filipovich A et al. Davies S High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12: 235-4.
130. Jansen J, Akard LP, Wack MF et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses 2006; 49: 397-404.
131. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised- controlled trials. Br J Haematol 2005; 131: 22-8.
132. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005; 56(Suppl 1): i23-33.
133. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
134. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
135. Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331-6.
136. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356: 348-59.
137. Ullmann AJ, Lipton JH, Vesole DH et al. Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
138. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis: a contraindication to marrow transplantation?. Blood 1994; 84: 2811-14.
139. Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-8.
140. Vaidya SJ, Ortin M, Lopez-Duarte M et al. Haemopoietic progenitor cell transplantation in patients with previous history of invasive fungal infection. Leuk Lymphoma 2005; 46: 1143-5.
141. Hermann S, Klein SA, Jacobi V et al. Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 2001; 113: 446-54.
142. A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-36.
143. Arathoon EG, Gotuzzo E, Noriega LM et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-7.
144. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
145. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
146. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
147. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215-22.
148. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
149. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-44.
150. Kontoyiannis DP, Lewis RE, Sagar N et al. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 2000; 44: 2915-18.
151. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
152. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
153. Marty FM, Lowry CM, Cutler CS et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 552-9.
154. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
155. Gubbins PO, Krishna G, Sansone-Parsons A et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50: 1993-9.
156. Sansone-Parsons A, Krishna G, Martinho M et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825-34.
157. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am 2002; 16: 915-33, vi-vii.
158. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipient. Clin Infect Dis 2004; 38: 1237-42.
159. Roilides E, Holmes A, Blake C et al. Effects of granulocyte colony-stimulating factor and interferon- g on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995; 57: 651-6.
160. Volpi I, Perruccio K, Tosti A et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotypemismatched hematopoietic transplants. Blood 2001; 97: 2514-21.
161. Cutler JE, Deepe GS, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007; 5: 13-28.
162. Ito JI, Lyons JM, Hong TB et al. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun 2006; 74: 5075-84.
163. Bacci A, Montagnoli C, Perruccio K et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol 2002; 168: 2904-13.
164. Bellocchio S, Bozza S, Montagnoli C et al. Immunity to Aspergillus fumigatus: the basis for immunotherapy and vaccination. Med Mycol 2005; 43(Suppl 1): S181-8.
165. BiMansour A, Burns SM, Traver D et al. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood 2002; 100: 4660-7.
166. Arber C, Bitmansour A, Shashidhar S et al. Protection against lethal Aspergillus fumigatus infection in mice by allogeneic myeloid progenitors is not major histocompatibility complex restricted. J Infect Dis 2005; 192: 1666-71.
167. Fernandez MN, Regidor C, Cabrera R et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive cotransplantation of a low number of highly purified peripheral blood CD34+ cells from an HLAhaploidentical donor. Exp Hematol 2003; 31: 535-44.
168. Mousset S, Hermann S, Klein SA et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005; 84: 734-41.
169. Safdar A, Hanna HA, Boktour M et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective casecontrol analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101: 2859-65.
170. Boiron JM, Dazey B, Cailliot C et al. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. Transfusion 2006; 46: 1934-42.
171. Gossot D, Validire P, Vaillancourt R et al. Full thoracoscopic approach for surgical management of invasive pulmonary aspergillosis. Ann Thorac Surg 2002; 73: 240-4.
172. Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing. Infect Dis Clin North Am 2006; 20: 699-709.
173. Alangaden G, Chandrasekar PH, Bailey E et al. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 1994; 6: 919-24.
174. Ehninger G, Schuler HK, Sarnow E. Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation. Mycoses 1996; 7-8: 259-63.
175. Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 2: 300-5.
176. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999; 10: 1089-93.
177. Wolff SN, Fay J, Stevens D, Herzig RH et al. Fluconazole vs. low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 8: 853-9.
178. Riley DK, Pavia AT, Beatty PG et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 6: 509-14.
179. Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 6: 577-82.
180. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 2: 163-8.